DURVALUMAB

Brand name:

• Imfinzi®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Small cell lung cancer (SCLC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Major submission)

Comment:

--

Other PBAC consideration:

--

Submission received for:

November 2020 PBAC meeting

Opportunity for consumer comment:

Open 26/08/2020 and close 07/10/2020 (see PBS Website)

PBAC meeting:

Held on 04/11/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/06/2023

Lodgement of required documentation:

02/08/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 04/09/2023

Status:

Finalised

Government processes:

Commenced on 25/09/2023

Medicine listed on the PBS:

01/12/2023 (see PBS schedule)